Novel SLE Index Enhances Prognostic Evaluation in Pancreatic Cancer Post Neoadjuvant Treatment

Patients with modest radiologic response to neoadjuvant treatment (NAT) for pancreatic cancer face operative eligibility uncertainties. A novel Sialyl-Lewis Antigen-related Index (SLE Index) combining CA19-9 and Dupan-II reveals significant prognostic value. An SLE Index below 45.25 correlates with favorable disease-free survival, proving superior in predicting recurrence within 24 months compared to individual tumor markers. This index, assessing multiple biologic factors, offers a simplified and effective tool for enhancing patient selection post-NAT.